RxDoctor Payments Data

Kester Nedd, DO

Neurology · Miami Lakes, FLNPI 1669499604

Payments from drug & device makers

$354,515in general payments, 2019–2025

Across 469 payments — averaging $755.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$311K
  • Sanofi$25K
  • Avanir Pharmaceuticals, Inc.$9K
  • AbbVie$1K
  • UCB, Inc.$1K
  • Amgen$558
  • plus $6K from 54 others
$2,154in research payments, 2019–2025

Across 2 payments — averaging $1077.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Speaking & faculty fees$7,91743%
  • Travel & lodging$5033%
  • Food & beverage$9,96754%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly1$310,639
Sanofi2$25,494
Avanir Pharmaceuticals, Inc.12$8,809
AbbVie(2 entities)73$1,351
UCB, Inc.34$1,350
Amgen(2 entities)23$558
Novartis21$465
Pfizer24$415
Eisai Inc.20$396
SK Life Science, Inc.13$382
Argenx US, Inc.15$331
Neurocrine Biosciences, Inc.28$325
AstraZeneca19$312
Biohaven Pharmaceuticals, Inc.13$271
Adamas Pharmaceuticals, Inc.18$258
Biohaven Pharmaceutical Holding Company Ltd.10$209
GE HealthCare11$169
Neurelis, Inc.9$165
Sumitomo Pharma America, Inc.6$145
Ipsen Biopharmaceuticals, Inc2$131
Upsher-smith Laboratories LLC6$125
Amneal Pharmaceuticals LLC8$117
Biogen6$112
Tanabe Pharma America, Inc.5$111
Lilly USA, LLC6$108
Mallinckrodt Hospital Products Inc.3$97
EMD Serono, Inc.4$96
Teva Pharmaceuticals USA, Inc.5$91
Scilex Pharmaceuticals Inc.5$89
Livanova USA, Inc.4$87
Idorsia Pharmaceuticals US Inc4$82
Saol Therapeutics Inc.1$79
Octapharma USA, Inc.3$76
Lundbeck LLC3$74
Collegium Pharmaceutical, Inc.4$73
Axsome Therapeutics, Inc.3$71
Otsuka America Pharmaceutical, Inc.4$64
Takeda Pharmaceuticals U.S.A., Inc.5$61
Acadia Pharmaceuticals Inc3$57
Boston Scientific1$55
Aprecia Pharmaceuticals, LLC3$53
Acorda Therapeutics, Inc3$51
Merck2$44
Supernus Pharmaceuticals, Inc.3$44
Merz Pharmaceuticals, LLC2$38
Genentech USA, Inc.2$35
Aquestive Therapeutics, Inc.2$35
ANI Pharmaceuticals, Inc.1$33
Microtransponder, Inc.1$28
Johnson & Johnson1$26
Catalyst Pharmaceuticals, Inc.1$24
Merz North America, Inc.1$24
Sunovion Pharmaceuticals Inc.1$23
Servier Pharmaceuticals LLC1$22
Tersera Therapeutics LLC1$22
Grifols USA, LLC1$18
Vertical Pharmaceuticals, LLC1$17
Piramal Critical Care1$16
Impel Pharmaceuticals Inc.1$16
Avion Pharmaceuticals1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$354,515 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$121,186
Medicare patients
323
Services billed
840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine81$118,570
BiktarvyBictegrav/Emtricit/Tenofov Ala11$43,950
DepakoteDivalproex Sodium12$16,147
OxycontinOxycodone Hcl12$9,780
QuviviqDaridorexant Hcl12$7,693
Lacosamide21$7,139
BelsomraSuvorexant17$7,111
TegretolCarbamazepine12$5,174
Clobazam18$4,455
Lamotrigine257$4,349
AmantadineAmantadine Hcl65$3,080
Levetiracetam52$2,409
Gabapentin211$2,400
Pregabalin62$2,323
Ziprasidone Hcl23$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$8,809$118,57081 claims
Idorsia Pharmaceuticals US IncQuviviq$82$7,69312 claims
MerckBelsomra$44$7,11117 claims
Upsher-smith Laboratories LLCTopiramate$125$25531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →